NCT04768881 2024-08-23
Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma
Karyopharm Therapeutics Inc
Phase 2 Terminated
Karyopharm Therapeutics Inc
Karyopharm Therapeutics Inc
Weill Medical College of Cornell University
Georgetown University
Karyopharm Therapeutics Inc
Karyopharm Therapeutics Inc
Karyopharm Therapeutics Inc
Karyopharm Therapeutics Inc
Karyopharm Therapeutics Inc
St. Jude Children's Research Hospital
Ohio State University Comprehensive Cancer Center